期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多发性骨髓瘤治疗进展 被引量：6

下载PDF
导出
摘要 多发性骨髓瘤(MM)是一种恶性浆细胞疾病,约占所有血液系统恶性肿瘤10.0%左右。目前仍为难以治愈性疾病,通过治疗以控制其进展、改善患者的生活质量、延长无病生存期为主要目标。随着新药的不断出现:免疫调节剂、蛋白酶体抑制剂、二代蛋白酶体抑制剂(Carfilzomib、NPI-0052等)、法尼基转移酶抑制剂、组蛋白去乙酰化酶(HDAC)抑制剂、热休克蛋白(HSP)抑制剂等以及单克隆抗体治疗MM,目前已在临床试验中,并取得了可喜的成果,使多发性骨髓瘤治疗的有效率、临床缓解率、无病生存率均有较大提高。现对MM的国内外最新药物治疗进行综述。
作者 马勇 汪兴洪
机构地区 皖南医学院弋矶山医院血液科
出处 《亚太传统医药》 2012年第4期201-203,共3页 Asia-Pacific Traditional Medicine
关键词 骨髓瘤 免疫治疗 骨髓治疗
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1MERCHIONNE F,PEROSA F,DAMMACCO F. New therapies in multiple myeloma[J].Clinical and Experimental Medicine,2007,(04):83-97.doi:10.1016/j.physbeh.2009.02.006.
  • 2SCHWARTZ RN,VOZNIAK M. Current and emerging treat ments for multiple myeloma[J].JOURNAL OF MANAGED CARE PHARMACY,2008,(7 suppl):12-18.
  • 3MORGAN G. Future drug developments in multiple myelo ma:an overview of novel lenalidomide based combination therapies[J].Blood Reviews,2010,(Suppl1):S2732.
  • 4SCHEY S A,FIELDS P,BARTLETT J B,CLARKE I A ASHAN G KNIGHT R D. Phase Ⅰ study of an immuno modulatory thalidomide analog,CC-4047,in relapsed or refractory multiple myeloma[J].Journal of Clinical Oncology,2004,(10):3269-3278.
  • 5ALSINA M,FONSECA R,WILBON EF. The farnesyl trans ferase inhibitor zarmtra is well tolerated.induceses stabilization of disease and inhibits farnesylation and oncogenicr/tumor Survival pathways in patients with advanced multiple myeloma[J].Blood,2004,(09):3271-3277.doi:10.1182/blood-2003-08-2764.
  • 6VAN DE DONK NW,LOKHORST HM,DIMOPOULOS M. Treatment of relapsed and refractory multiple myeloma in the era of novel agents[J].Cancer Treat Rcv,2010,(04):266-283.
  • 7MORGAN GL,DAVIES FE,GREGORY WM. Firstline theatment with zoledronic acid as compared with clodron ic acid in multiple myeloma(MRC Myeloma Ⅸ):a randomized controlled trial[J].Lancet,2010,(9757):19891999.doi:10.1016/S0140-6736(10)62051-X.
  • 8WEINTRAUB B. Trials define anti tumor effects of anti-resorptive angents:denosumab ahead of zoledronate 2 to I[J].Biodrugs:Clinical Immunotherapeutics,Biopharmaceuticals and Gene Therapy,2011,(02):135-138.doi:10.2165/11590730-000000000-00000.
  • 9WANG JING. Myeloma Bone Disease Current and Future Treatment[M].A Publication of The Bone and Cancer Foundation,2008.
  • 10ZAVRSKI I,KREBBEL.H,WILDEMANN B. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function[J].Biochemical and Biophysical Research Communications,2005,(01):200-205.doi:10.1016/j.bbrc.2005.05.098.

同被引文献51

  • 1杨秀,王庆文,王金泉,陈惠萍,曾彩虹,刘志红,黎磊石,金洁.多发性骨髓瘤肾损害尿蛋白性质的分析及临床意义[J].医学研究生学报,2007,20(3):290-294. 被引量：8
  • 2张之南,沈悌.血液病诊断及疗效栋准[M].3版.北京:科学出版社,1999:232-235.
  • 3Hideshlma T, Raje N, Richardson PG,et al. A review oflenalidomide in combination with dexamethasone for thetreatment of multiple myeloma[J].Ther Clin Risk Manag,2008,4(1):129-136.
  • 4Bade J,Bosinol L,Cibeira MT,et al.Hematopoietic stem cell transplantation for multiple beyond 2010[J].Blood,2010,115:3655-3663.
  • 5Paul G.Barb B,et al.Extended follow up of a phase II trialIn relapsed,refractory multiple myeloma[J].Cancer,2006,106:1316-1319.
  • 6Bruno B,Rotta M,Patriarca F,et al.A comparison of allografting with autografting for newly diagnosed myeloma[J].N Eng l J Med,2007,356:1110-1120.
  • 7Kukreja A,Hutchinson A,Dhodapkar K,et al.Enhancement of clonogenicity of human multiple myeloma by dendritic cells[J].J Exp Med,2006,203:185918-185965.
  • 8Rozkova D,Tiserova H,Fucikova J,et al.FOCUS on FOCIS:Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer[J].Clin Immunol,2009,131:1-10.
  • 9Pievani A.Belussi C,Klein C,et al.Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell(CIK)cultures and anti-CD20 antibodies[J].J Immunol,2011,117:510-518.
  • 10Di Bernardo A,Macor P,Guarnotta C,et al.Humoral immunotherapy of multiple myeloma:perspectives and perplexities[J].Expert Opin Biol The,2010,10:863-873.

引证文献6

二级引证文献15

亚太传统医药
2012年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部